2023, Número 5
<< Anterior Siguiente >>
Med Int Mex 2023; 39 (5)
Factores de riesgo asociados con mortalidad en pacientes con mucormicosis rino-órbito-cerebral y COVID-19
Quintero BA, Lugo MJA, Sainz FN, Arellano RIC, Canche MEM, Reina LJR, Rodríguez QOS, Rodríguez RPA
Idioma: Español
Referencias bibliográficas: 45
Paginas: 734-742
Archivo PDF: 240.45 Kb.
RESUMEN
Objetivo: Identificar los factores de riesgo asociados con mortalidad en pacientes
con mucormicosis rino-órbito-cerebral y COVID-19.
Materiales y Métodos: Estudio observacional, analítico, transversal y retrospectivo,
efectuado en pacientes con mucormicosis rino-órbito-cerebral de enero de 2020
a octubre de 2022. Se aplicaron estadísticas descriptivas, para el análisis inferencial
se utilizó U de Mann-Whitney y χ
2 de Pearson, así como razón de momios (RM) para
determinar el riesgo; se consideró significativo un valor de p menor de 0.05.
Resultados: Se incluyeron 15 pacientes, de 60.87 años en promedio, 9 de ellos
del sexo masculino. No se encontraron diferencias entre vivos y muertos en cuanto al
sexo, localización de la mucormicosis, ni la gravedad de COVID-19. Se encontraron
diferencias entre el número de comorbilidades (p = 0.035) y el tipo de tratamiento
quirúrgico (p = 0.039). Al evaluar el riesgo de muerte y sexo se obtuvo una RM de 0.125
(IC95% 0.009-1.723), localización de la enfermedad: RM de 0.30 (IC95% 0.014-6.382),
grado de enfermedad por COVID-19: RM de 10 (IC95% 0.584-171.202), estadio por
tomografía: RM de 4.500 (IC95% 0.374-54.155), tipo de tratamiento quirúrgico: RM
de 13.500 (IC95% 0.878-207.624).
Conclusiones: Los factores asociados con mortalidad en pacientes con mucormicosis
rino-órbito-cerebral y COVID-19 fueron tener dos o más comorbilidades y el
tipo de tratamiento quirúrgico.
REFERENCIAS (EN ESTE ARTÍCULO)
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, SarkisovaTA, Schaufele RL, et al. Epidemiology and outcome ofzygomycosis: A review of 929 reported cases. Clin InfectDis 2005; 41 (5): 634-653. https://doi.org/10.1086/432579.
Binder U, Maurer E, Lass-Flörl C. Mucormycosis - from thepathogens to the disease. Clin Microbiol Infect 2014; 20Suppl 6: 60-6. doi: 10.1111/1469-0691.12566.
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, KongDCM, et al. The epidemiology and clinical manifestationsof mucormycosis: a systematic review and meta-analysisof case reports. Clin Microbiol Infect 2019; 25 (1): 26-34.doi: 10.1016/j.cmi.2018.07.011.
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ,Kontoyiannis DP. Epidemiology and clinical manifestationsof mucormycosis. Clin Infect Dis 2012; 54 (Suppl. 1): S23-34.doi: 10.1093/cid/cir866.
Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL.The epidemiological features of invasive mycotic infectionsin the San Francisco Bay Area, 1992-1993: Results ofpopulation-based laboratory active surveillance. Clin InfectDis 1998; 27 (5): 1138-47.
Nagalli S, Kikkeri NS. Mucormycosis in COVID-19: A systematicreview of literature. Infez Med 2021; 29: 504-12. doi:10.53854/liim-2904-2.
Köhler JR, Hube B, Puccia R, Casadevall A, Perfect JR.Fungi that infect humans. Microbiol Spectr 2017; 5 (3).doi: 10.1128/microbiolspec.FUNK-0014-2016.
Nucci M, Engelhardt M, Hamed K. Mucormycosis in SouthAmerica: A review of 143 reported cases. Mycoses 2019;62: 730-8. doi: 10.1111/myc.12958.
Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E,Petrikkos G. Challenges in the diagnosis and treatmentof mucormycosis. Med Mycol 2018; 56: S93-101. doi:
10.1093/mmy/myx101.10. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis.J Fungi 2019; 5 (1): 26. doi: 10.3390/jof5010026.
Steinbrink JM, Miceli MH. Mucormycosis. Infect Dis ClinNorth Am 2021; 35: 435-52. doi: 10.1016/j.idc.2021.03.009.
Petrikkos G, Tsioutis C. Recent advances in the pathogenesisof mucormycoses. Clin Ther Excerpta Medica 2018; 40:894-902. doi: 10.1016/j.clinthera.2018.03.009.
Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis—The bitter and the sweet. PLoS Pathog 2017; 13. doi:10.1371/journal.ppat.1006408.
Roilides E, Antachopoulos C, Simitsopoulou M. Pathogenesisand host defense against Mucorales: The role ofcytokines and interaction with antifungal drugs. Mycoses2014; 57 (s3): 40-7. doi: 10.1111/myc.12236.
Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis(mucormycosis): emerging clinical importance and newtreatments. Curr Opin Infect Dis 2004; 17 (6): 517-25. doi:10.1097/00001432-200412000-00003.
World Health Organization. Director-General’s remarks atthe media briefing on 2019-nCoV on 11 February 2020.https://www.who.int/es/director-general/speeches/detail/who-director-general-s-remarks-at-the-mediabriefing-on-2019-ncov-on-11-february-2020. 2020.
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C,Gulyaeva AA, et al. The species severe acute respiratorysyndrome-related coronavirus: classifying 2019-nCoV andnaming it SARS-CoV-2. Nature Microbiol 2020; 5: 536-44.https://doi.org/10.1038/s41564-020-0695-z.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, HerrlerT, Erichsen S, et al. SARS-CoV-2 cell entry depends onACE2 and TMPRSS2 and is blocked by a clinically provenprotease inhibitor. Cell 2020; 181 (2): 271-280.e8. doi:10.1016/j.cell.2020.02.052.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinicalfeatures of patients infected with 2019 novel coronavirus inWuhan, China. Lancet 2020; 395 (10223): 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
Hussain S, Riad A, Singh A, Klugarová J, Antony B, Banna H,et al. Global prevalence of COVID-19-associated mucormycosis(CAM): Living systematic review and meta-analysis. JFungi 2021; 7 (11). doi: 10.3390/jof7110985.
Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I,Sharma R, et al. Multicenter epidemiologic study of coronavirusdisease-associated mucormycosis, India. Emerg InfectDis 2021; 27 (9): 2349-59. doi: 10.3201/eid2709.210934.
Nucci M, Engelhardt M, Hamed K. Mucormycosis in SouthAmerica: A review of 143 reported cases. Mycoses 2019;62: 730-8. doi: 10.1111/myc.12958.
Code Mucor: Guidelines for the Diagnosis, Staging andManagement of Rhino-Orbito-Cerebral Mucormycosis inthe Setting of COVID-19. 2021.
Janjua OS, Shaikh MS, Fareed MA, Qureshi SM, Khan MI,Hashem D, et al. Dental and oral manifestations of COVID-19 related mucormycosis: diagnoses, managementstrategies and outcomes. J Fungi 2022; 8: 44. doi: 10.3390/jof8010044.
Pippal SK, Kumar D, Ukawat L. Management challengeof rhino-orbito-cerebral mucormycosis in Covid 19 era: aprospective observational study. Indian J Otolaryngol HeadNeck Surgery 2022; 74 (Suppl 2): 3485-3491.; doi: 10.1007/s12070-021-02947-5.
Safi M, Ang MJ, Patel P, Silkiss RZ. Rhino-orbital-cerebralmucormycosis (ROCM) and associated cerebritis treatedwith adjuvant retrobulbar amphotericin B. Am J OphthalmolCase Rep. 2020; 19. doi: 10.1016/j.ajoc.2020.100771.
Lee AS, Lee PWY, Allworth A, Smith T, Sullivan TJ. Orbitalmycoses in an adult subtropical population. Eye (Basingstoke).2020; 34 (9): 1640-7. https://doi.org/10.1038/s41433-019-0733-3.
Satish D, Joy D, Ross A, Balasubramanya. Mucormycosis coinfectionassociated with global COVID-19: a case series fromIndia. Int J Otorhinolaryngol Head Neck Surg 2021; 7 (5).
Fouad YA, Abdelaziz TT, Askoura A, Saleh MI, Mahmoud MS,Ashour DM, et al. Spike in rhino-orbital-cerebral mucormycosiscases presenting to a tertiary care center during theCOVID-19 pandemic. Front Med (Lausanne) 2021; 8. doi:10.3389/fmed.2021.645270.
Ashour MM, Abdelaziz TT, Ashour DM, Askoura A, Saleh MI,Mahmoud MS. Imaging spectrum of acute invasive fungalrhino-orbital-cerebral sinusitis in COVID-19 patients: A caseseries and a review of literature. J Neuroradiol 2021; 48(5). doi: 10.1016/j.neurad.2021.05.007.
Bayram N, Ozsaygılı C, Sav H, Tekin Y, Gundogan M, PangalE, et al. Susceptibility of severe COVID-19 patients torhino-orbital mucormycosis fungal infection in differentclinical manifestations. Jpn J Ophthalmol 2021; 65 (4). doi:10.1007/s10384-021-00845-5.
Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, MehrparvarG, et al. Mucormycosis in patients with COVID-19:A cross-sectional descriptive multicentre study from Iran.Mycoses 2021; 64 (10). doi: 10.1111/myc.13334.
Guzmán-Castro S, Chora-Hernandez LD, Trujillo-Alonso G,Calvo-Villalobos I, Sanchez-Rangel A, Ferrer-Alpuin E, et al.COVID-19–associated mucormycosis, diabetes and steroidtherapy: Experience in a single centre in Western Mexico.Mycoses 2022; 65 (1): 65-70. doi: 10.1111/myc.13383.
Soni S, Namdeo Pudake R, Jain U, Chauhan N. A systematicreview on SARS-CoV-2-associated fungal coinfections. JMed Virol 2022; 94: 99-109. doi: 10.1002/jmv.27358.
Rabagliati R, Rodríguez N, Núñez C, Huete A, Bravo S,Garcia P. Covid-19-associated mold infection in critically illpatients, Chile. Emerg Infect Dis 2021; 27 (5). doi: 10.3201/eid2705.204412.
Mishra N, Mutya VSS, Thomas A, Rai G, Reddy B, M. AA,et al. A case series of invasive mucormycosis in patientswith COVID-19 infection. Int J Otorhinolaryngol Head NeckSurg 2021; 7 (5). https://doi.org/10.18203/issn.2454-5929.ijohns20211583.
Yadav H, Sen S, Nath T, Mazumdar S, Jain A, Verma P, etal. Analysis of COVID-19-associated rhino-orbital-cerebralmucormycosis patients in a tertiary care center in NorthernIndia. Indian J Ophthalmol 2022; 70 (6): 2163-8. DOI:10.4103/ijo.IJO_340_22.
Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK,Kale PG, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids—an unholy trinity in invasive fungal infectionsof the maxillofacial region? A retrospective, multi-centricanalysis. J Maxillofac Oral Surg 2021; 20 (3). doi: 10.1007/s12663-021-01532-1.
Sekaran A, Patil N, Sabhapandit S, Sistla SK, Reddy DN.Rhino-orbito-cerebral mucormycosis: an epidemic in apandemic. IJID Regions 2022; 2. https://doi.org/10.1016/j.ijregi.2021.12.009.
Gandhi A, Narula A, Chandra S, Agarwal D, Mehta A, NayakS, et al. Battling the emerging epidemic of rhino-orbitalcerebralmucormycosis (ROCM) in COVID-19 pandemic: aninterventional study. Int Ophthalmol 2022; 43 (5): 1571-1580. doi: 10.1007/s10792-022-02556-3.
Kangro K, Wolberg AS, Flick MJ. Fibrinogen, fibrin, andfibrin degradation products in COVID-19. Curr Drug Targets2022; 23 (17): 1593-1602. doi: 10.2174/1389450123666220826162900.
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis inCOVID-19: A systematic review of cases reported worldwideand in India. Diabetes Metab Syndr 2021; 15 (4). doi:10.1016/j.dsx.2021.05.019.
Riad A, Shabaan AA, Issa J, Ibrahim S, Amer H, Mansy Y, etal. COVID-19-associated mucormycosis (Cam): Case-seriesand global analysis of mortality risk factors. J Fungi 2021;7 (10). doi: 10.3390/jof7100837.
Zirpe K, Pote P, Deshmukh A, Gurav SK, Tiwari AM, SuryawanshiP. A retrospective analysis of risk factors of COVID-19associated mucormycosis and mortality predictors: Asingle-center study. Cureus 2021; 13 (10): e18718. doi:10.7759/cureus.18718.
Bhatt K, Agolli A, H. Patel M, Garimella R, Devi M, GarciaE, et al. High mortality co-infections of COVID-19 patients:mucormycosis and other fungal infections. Discoveries2021; 9 (1): e126. doi: 10.15190/d.2021.5.